1-2 of 2
Mojca Lavrencic, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Jan J Cornelissen, MD PhD, Alois Gratwohl, MD, Kees GM van Montfort, Thomas Pabst, MD, Johan Maertens, MD, H. Berna Beverloo, PhD, Marinus van Marwijk Kooy, P.W. Wijermans, MD, PhD, Bart J Biemond, MD, Dimitri A. Breems, MD, PhD, Edo Vellenga, PhD, Leo F Verdonck, Martin F. Fey, MD, Mojca Lavrencic, MD, PhD, Jeroen JWM Janssen, MD PhD, Gerwin Huls, Jurgen Kuball, MD, PhD, Jakob R. Passweg, MD, Carlos Graux, MD, PhD, Harry C. Schouten, MD, PhD, Gert Ossenkoppele, MD, PhD, Bob Lowenberg, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 159.
https://doi.org/10.1182/blood.V118.21.159.159
Published: 2011
Journal Articles

High Prognostic Impact of Mixed Chimerism of Blood and Marrow In the First Year After Allogeneic Hematopoietic Stem Cell Transplantation: The Need to Rapidly Establish Complete Donor Chimerism.

Ellen Meijer, MD, PhD, Lucia Duinhouwer, Eric Braakman, PhD, Joke Boonstra, PhD, Inge de Greef, MD, PhD, Jeanette Doorduijn, MD, PhD, Mojca Lavrencic, MD, PhD, Bob Lowenberg, MD, PhD, Jan Cornelissen, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3464.
https://doi.org/10.1182/blood.V116.21.3464.3464
Published: 2010